Abstract
High rates of hepatitis B virus (HBV) infection and primary liver cancer (PLC) are present in Qidong county. Epidemiological surveys demonstrated an inverse association between selenium (Se) level and regional cancer incidence, as well as HBV infection. Four-year animal studies showed that dietary supplement of Se reduced the HBV infection by 77.2% and liver precancerous lesion by 75.8% of ducks, caused by exposure to natural environmental etiologic factors. An intervention trial was undertaken among the general population of 130,471. Individuals in five townships were involved for observation of the preventive effect of Se. The 8-yr follow-up data showed reduced PLC incidence by 35.1% in selenized table salt supplemented vs the nonsupplemented population. On withdrawal of Se from the treated group, PLC incidence rate began to increase. However, the inhibitory response to HBV was sustained during the 3-yr cessation of treatment. The clinical study among 226 Hepatitis B Surface Antigen (HBsAg)-positive persons provided either 200 μg of Se in the form of selenized yeast tablet or an identical placebo of yeast tablet daily for 4 yr showed that 7 of 113 subjects were diagnosed as having PLC in the placebo group, whereas no incidence of PLC was found in 113 subjects supplemented with Se. Again on cessation of treatment, PLC developed at a rate comparable to that in the control group, demonstrating that a continuous intake of Se is essential to sustain the chemopreventive effect.
Similar content being viewed by others
References
R. P. Beasley and C. C. Lin, Hepatoma risk among HBsAg carriers,Am. J. Epidemiol. 108, 247 (1978).
W. G. Li, and L. Q. Shao, Experimental study on selenic blockage of primary hepatocarcinoma induced by aflatoxin B1 in rats.Chinese J. Prevent. Med. 21, 11–12 (1987).
S. Y. Yu, Y. J. Zhu, and W. G. Li, Selenium chemoprevention of liver cancer in animals and possible human application,Biol. Trace Element Res. 15, 231–241 (1988).
J. E. Spallholz, Selenium: What role in immunity and immune cytotoxcity, in:Selenium in Biology and Medicine, J. E. Spallholz, J. L. Martin, and H. E. Ganther, eds., Westport, CT, pp. 103–117 (1981).
J. E. Spallholz, Anti-inflammatory, Immunologic and Carcinostatic Attributes of Selenium in Experimental Animals, in:Diet and Resistance of Disease, M. Phillips and A. Beetz, eds., Plenum, New York, pp. 43–62, (1981).
L. D. Koller, J. H. Exon, P. A. Talcott, C. A. Osborne, and G. M. Henningsen, Immune response in rats supplemented with selenium.Clin. Exp. Immunol. 63, 570–576 (1986).
S. Y. Yu, P. Ao, L. M. Wang, S. L. Huang, H. C. Chen, X. P. Lu, and Q. Y. Liu, Biochemical and cellular aspects of the anticancer activity of selenium.Biol. Trace Element Res. 15, 243–255 (1988).
S. Y. Yu, X. P. Lu, and S. D. Liao, The regulatory effect of selenium on the expression of oncogenes associated with proliferation and differentiation on tumor cells, in:Metal Ions in Biology and Medicine, P. H. Collory, L. A. Poirier, M. Manfait, and J. C. Etienne, eds., Libbey Eurotext, Paris, pp. 487–489 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yu Yu, S., Zhu, Y.J. & Li, W.G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 56, 117–124 (1997). https://doi.org/10.1007/BF02778987
Issue Date:
DOI: https://doi.org/10.1007/BF02778987